A detailed history of Pathstone Family Office, LLC transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Pathstone Family Office, LLC holds 425,492 shares of ATHA stock, worth $285,079. This represents 0.01% of its overall portfolio holdings.

Number of Shares
425,492
Previous 425,492 -0.0%
Holding current value
$285,079
Previous $1.26 Million 31.55%
% of portfolio
0.01%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$2.26 - $4.22 $3.14 Million - $5.87 Million
-1,390,048 Reduced 76.56%
425,492 $1.06 Million
Q3 2022

Oct 23, 2023

BUY
$2.93 - $3.96 $371,231 - $501,732
126,700 Added 7.5%
1,815,540 $5.66 Million
Q3 2022

Nov 14, 2022

BUY
$2.93 - $3.96 $371,231 - $501,732
126,700 Added 7.5%
1,815,540 $5.39 Million
Q2 2022

Oct 23, 2023

BUY
$2.74 - $13.43 $3.46 Million - $17 Million
1,263,348 Added 296.91%
1,688,840 $5.15 Million
Q2 2022

Aug 15, 2022

BUY
$2.74 - $13.43 $162,482 - $796,399
59,300 Added 3.64%
1,688,840 $5.15 Million
Q1 2022

May 16, 2022

BUY
$8.96 - $13.51 $1.68 Million - $2.53 Million
187,293 Added 12.99%
1,629,540 $22 Million
Q4 2021

Feb 14, 2022

BUY
$9.17 - $16.39 $2.71 Million - $4.85 Million
295,800 Added 25.8%
1,442,247 $18.8 Million
Q3 2021

Nov 16, 2021

BUY
$9.15 - $11.09 $4.44 Million - $5.38 Million
484,835 Added 73.28%
1,146,447 $10.8 Million
Q2 2021

Aug 31, 2021

BUY
$10.24 - $20.87 $1.66 Million - $3.39 Million
162,196 Added 32.48%
661,612 $6.78 Million
Q1 2021

May 14, 2021

BUY
$16.9 - $29.77 $7.06 Million - $12.4 Million
417,533 Added 509.91%
499,416 $9.19 Million
Q4 2020

Feb 16, 2021

SELL
$16.48 - $34.3 $46,407 - $96,588
-2,816 Reduced 3.32%
81,883 $2.8 Million
Q3 2020

Nov 12, 2020

BUY
$16.02 - $18.46 $1.36 Million - $1.56 Million
84,699 New
84,699 $1.56 Million

Others Institutions Holding ATHA

About Athira Pharma, Inc.


  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $25.3M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Pathstone Family Office, LLC Portfolio

Follow Pathstone Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Family Office, LLC with notifications on news.